Joseph Geraci
Chief Tech/Sci/R&D Officer at NETRAMARK HOLDINGS INC.
Net worth: 932 535 $ as of 2024-03-30
Profile
Joseph Geraci is the founder of NetraMark Corp., which was founded in 2016.
He holds the title of Chief Executive Officer at NetraMark Corp.
Dr. Geraci's current job is as a Director, Chief Scientific & Technology Officer at NetraMark Holdings, Inc. Dr. Geraci's former job was as the Chief Scientific Officer at Open Source Health, Inc. Dr. Geraci has a doctorate degree from the University of Southern California and graduate and doctorate degrees from the University of Toronto.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
NETRAMARK HOLDINGS INC
6.01% | 2024-03-27 | 4,002,298 ( 6.01% ) | 932 535 $ | 2024-03-30 |
Joseph Geraci active positions
| Companies | Position | Start |
|---|---|---|
| NETRAMARK HOLDINGS INC. | Chief Tech/Sci/R&D Officer | 2021-10-17 |
NetraMark Corp.
 NetraMark Corp. Information Technology ServicesTechnology Services Part of NetraMark Holdings, Inc., NetraMark Corp. is an AI and pharma-tech company based in Toronto, CA. NetraMark was acquired by NetraMark Holdings, Inc. on October 18, 2021 for $11.92 million. The private company focuses on developing AI/ML solutions for the pharmaceutical industry, using a novel topology-based algorithm to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. NetraMark's proprietary next-generation AI solutions for pharmaceutical and biotechnology companies allow them to leverage small to large data sets in order to prevent clinical trial failure, identify biomarkers, implement adaptive trials, accelerate drug discovery, and enable drug repurposing and resurrection. The Canadian company was founded in 2016 by Joseph Geraci and Richard Brooks, with Joseph Geraci serving as CEO since then. | Chief Executive Officer | 2015-12-31 |
Former positions of Joseph Geraci
| Companies | Position | End |
|---|---|---|
Open Source Health, Inc.
 Open Source Health, Inc. Financial ConglomeratesFinance Open Source Health, Inc. operates as a capital pool company. The company was founded by Sonya Satveit and is headquartered in Calgary, Canada. | Chief Tech/Sci/R&D Officer | - |
Training of Joseph Geraci
| University of Southern California | Doctorate Degree |
| University of Toronto | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NETRAMARK HOLDINGS INC. | Technology Services |
| Private companies | 2 |
|---|---|
Open Source Health, Inc.
Open Source Health, Inc. Financial ConglomeratesFinance Open Source Health, Inc. operates as a capital pool company. The company was founded by Sonya Satveit and is headquartered in Calgary, Canada. | Finance |
NetraMark Corp.
NetraMark Corp. Information Technology ServicesTechnology Services Part of NetraMark Holdings, Inc., NetraMark Corp. is an AI and pharma-tech company based in Toronto, CA. NetraMark was acquired by NetraMark Holdings, Inc. on October 18, 2021 for $11.92 million. The private company focuses on developing AI/ML solutions for the pharmaceutical industry, using a novel topology-based algorithm to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. NetraMark's proprietary next-generation AI solutions for pharmaceutical and biotechnology companies allow them to leverage small to large data sets in order to prevent clinical trial failure, identify biomarkers, implement adaptive trials, accelerate drug discovery, and enable drug repurposing and resurrection. The Canadian company was founded in 2016 by Joseph Geraci and Richard Brooks, with Joseph Geraci serving as CEO since then. | Technology Services |
- Stock Market
- Insiders
- Joseph Geraci
